Eli Lilly and Company (NYSE:LLY) Shares Sold by UMB Bank n.a.

UMB Bank n.a. lessened its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 4.6% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 90,226 shares of the company's stock after selling 4,399 shares during the quarter. Eli Lilly and Company accounts for 1.2% of UMB Bank n.a.'s investment portfolio, making the stock its 19th largest position. UMB Bank n.a.'s holdings in Eli Lilly and Company were worth $74,519,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Mascagni Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $43,000. FPC Investment Advisory Inc. increased its holdings in Eli Lilly and Company by 358.3% during the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after acquiring an additional 43 shares in the last quarter. Prudent Man Investment Management Inc. purchased a new position in Eli Lilly and Company during the 4th quarter valued at about $48,000. Compass Financial Services Inc purchased a new position in Eli Lilly and Company during the 4th quarter valued at about $50,000. Finally, Capital A Wealth Management LLC purchased a new position in Eli Lilly and Company during the 4th quarter valued at about $63,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. The trade was a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $770.00 on Friday. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The firm has a 50 day moving average price of $770.87 and a 200 day moving average price of $800.27. The company has a market cap of $729.76 billion, a price-to-earnings ratio of 65.76, a PEG ratio of 1.40 and a beta of 0.40. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company's quarterly revenue was up 45.2% on a year-over-year basis. During the same period last year, the firm earned $2.58 earnings per share. Sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.78%. Eli Lilly and Company's dividend payout ratio (DPR) is 48.82%.

Wall Street Analysts Forecast Growth

LLY has been the subject of several recent research reports. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. UBS Group dropped their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Wall Street Zen upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday. Guggenheim restated a "buy" rating on shares of Eli Lilly and Company in a report on Friday, May 23rd. Finally, Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $1,011.37.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.